Peptides 101 · Peptide Guide
It’s one of the first questions people ask when they start exploring peptide therapy: do I actually need a prescription for this? The answer, frustratingly, is: it depends, and the details…
Peptides don’t sit neatly in one regulatory category. Some are FDA-approved drugs that require a prescription from a licensed physician. Some can be legally compounded by licensed pharmacies with a prescription. Some exist in a regulatory grey area. And some are sold online as “research chemicals” in a way that, while technically legal for the seller, is not legally sanctioned for human use.
Understanding which category a specific peptide falls into, and what that means practically, is the most important due diligence anyone can do before considering a protocol.
The most useful way to think about peptide access is through three broad categories, each with very different rules around prescription requirements, sourcing, and oversight.
✅ FDA-Approved Peptide Drugs
Prescription required: Yes, from a licensed physician
Examples:
💊 Compounded Peptides (with Rx)
Prescription required: Yes, from a licensed physician
Examples:
*Subject to ongoing regulatory review
⚠️ Research-Grade Peptides
Prescription required: No (sold OTC)
Legal for human use: No
The reality:
Some peptides have completed the full FDA drug approval process, rigorous clinical trials demonstrating safety and efficacy for specific indications, followed by manufacturing approval and post-market surveillance. These are unambiguously prescription medications and must be obtained through a licensed prescriber and a licensed pharmacy.[1]
The most prominent examples in this category are the GLP-1 receptor agonists: semaglutide (sold as Ozempic for type 2 diabetes and Wegovy for chronic weight management) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss). Insulin, in all its forms, is also a peptide drug, and one of the oldest prescription medications in use. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. PT-141 (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women.
For these peptides, the prescription pathway is the same as for any other pharmaceutical drug: you see a licensed physician, they evaluate your medical history and determine whether the medication is clinically appropriate, and they issue a prescription that can be filled at any licensed pharmacy. Many telehealth platforms also prescribe these medications following a medical consultation.
Important note on compounded GLP-1s
During drug shortage periods, compounding pharmacies were legally permitted to produce compounded versions of semaglutide and tirzepatide. As of early 2026, the FDA declared the drug shortages resolved, meaning compounded versions of these specific peptides can no longer be legally produced under shortage provisions. If you are using a compounded GLP-1, speak with your prescriber about your options.
Compounding pharmacies occupy a specific and carefully regulated niche in US pharmaceutical law. They are licensed to prepare customised medications for individual patients, but they operate under strict rules about which substances they can and cannot use.[2]
There are two types of compounding facilities relevant to peptides:
These are traditional compounding pharmacies that prepare medications for specific patients pursuant to a valid prescription. For peptides, a 503A pharmacy can only legally compound a substance if it meets one of these criteria: it is the active ingredient in an FDA-approved drug, it has a USP (United States Pharmacopeia) monograph, it appears on the FDA’s 503A Bulks List (Category 1), or it is in Category 1 of the interim bulks list.[3]
These are larger, FDA-registered outsourcing facilities that can produce larger batches without patient-specific prescriptions. They face stricter federal oversight than 503A pharmacies and must comply with Current Good Manufacturing Practice (CGMP) standards. For peptides, 503B facilities can only compound from bulk substances on the FDA’s 503B Bulks List, or final products on the FDA’s Drug Shortages List.
The FDA uses a category system to classify bulk drug substances nominated for compounding. Understanding this system is essential for understanding which peptides are currently legally accessible through compounding pharmacies:
Category 1, Eligible for Compounding
Substances the FDA has determined are eligible for compounding by licensed 503A pharmacies. These can be prepared for individual patients pursuant to a valid prescription. Examples include sermorelin and NAD+. As of February 2026, approximately 14 additional peptides previously in Category 2 are being moved to Category 1.
Category 2, Restricted / Prohibited for Compounding
Substances the FDA has identified as presenting potential safety risks and not currently eligible for routine compounding. Placement in Category 2 does not equal a formal drug prohibition, it means compounding pharmacies cannot legally prepare them for routine use. BPC-157, CJC-1295, ipamorelin, and TB-500 were placed in Category 2 in October 2023.
Category 3, Under Evaluation
Substances with insufficient information for full evaluation. The FDA’s Pharmacy Compounding Advisory Committee reviews these substances and makes recommendations about their eligibility for compounding. Placement here is a holding position while evidence is assessed.
In late 2023, the FDA moved 19 widely used peptides to Category 2, effectively prohibiting licensed compounding pharmacies from preparing them. This decision was controversial, many clinicians and compounding pharmacy groups argued the FDA overstated the risks for most affected compounds, given the absence of specific safety signals in the clinical literature.[4]
In late February 2026, HHS Secretary Robert F. Kennedy Jr. said he expected the FDA to change the status of about 14 of the 19 Category 2 peptides. No such change followed, and none of them can legally be compounded today.[5]
⚠️ Critical nuance: Removal from Category 2 does NOT mean these peptides are FDA-approved drugs. They remain off-label therapeutics, meaning they are not approved for any specific indication and their safety and efficacy have not been validated through the full FDA drug approval process. Physician supervision, proper dosing, and ongoing monitoring remain essential regardless of regulatory category.
A significant portion of the peptides discussed online and in wellness communities are sold not as pharmaceutical-grade medications, but as “research chemicals”, products sold under a Research Use Only (RUO) designation with disclaimers that they are “not for human consumption.”
These products do not require a prescription to purchase. But the absence of a prescription requirement does not make them legal or safe for human use. The FDA has been explicit: labelling a product “for research purposes only” or “not for human consumption” does not exempt it from drug regulations when it is clearly intended and marketed for human use. The agency has pursued enforcement action against vendors who made therapeutic claims or sold products alongside diluents and syringes, evidence of intended human use.[6]
Research-grade peptides also carry meaningful quality risks. Unlike pharmaceutical-grade compounds, they are not subject to USP manufacturing standards. Purity can vary dramatically, some products test as low as 60% purity. Contaminants including heavy metals have been identified in products from unregulated suppliers. There is no quality control, no certificate of analysis from a verified independent laboratory, and no recourse if a product harms you.
| Peptide | Prescription Required? | Current Status (US, 2026) |
|---|---|---|
| Semaglutide | Yes | FDA-approved drug (Ozempic, Wegovy). Compounded versions restricted following shortage resolution. |
| Tirzepatide | Yes | FDA-approved drug (Mounjaro, Zepbound). Compounding restrictions apply. |
| Insulin | Yes | FDA-approved. Available in many forms. Some OTC forms available in certain states. |
| Sermorelin | Yes | Compoundable under 503A (Category 1). Prescription from licensed physician required. |
| BPC-157 | Yes | Expected to return to Category 1 (Feb 2026 reclassification). Not FDA-approved. Requires Rx and licensed compounding pharmacy. |
| CJC-1295 / Ipamorelin | Yes | Expected to return to Category 1. Not FDA-approved. Requires Rx and licensed compounding pharmacy. |
| TB-500 | Yes | Expected to return to Category 1. Not FDA-approved. Requires Rx and licensed compounding pharmacy. |
| PT-141 (Bremelanotide) | Yes | FDA-approved (Vyleesi) for HSDD in premenopausal women. Prescription required. |
| Collagen peptides | No | Available OTC as dietary supplements. Not therapeutic peptides in the pharmaceutical sense. |
| GHK-Cu (topical) | No | Available OTC in skincare products. Regulated as cosmetic ingredient. |
The honest answer to “do I need a prescription for peptides?” is: for any therapeutic peptide that is worth considering, yes, you should want one, even if you could technically acquire it without one.
A prescription is not just a legal formality. It is the mechanism by which a licensed clinician takes medical responsibility for your protocol, reviewing your health history, ordering appropriate labs, confirming you are an appropriate candidate, sourcing a pharmaceutical-grade product from a regulated facility, and monitoring your response over time.
The peptides most likely to be effective are the same ones most likely to have physiological consequences. That combination, meaningful biological activity plus real risk, is precisely the scenario where professional oversight is most important, not least.
Our free quiz helps you understand your goals and whether a clinician-guided program might be relevant to your situation.